Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04113551 · ClinicalTrials.gov registry record
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
A clinical trial, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 17,418
- Enrollment target
NCT04113551 is a clinical trial that has completed, run by Janssen Research & Development. The registered enrollment target is 17,418 participants.
The verdict
NCT04113551 has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 17,418 participants
- Enrollment target
Study Summary
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
Interventions
- DRUG MPH (Concerta)
- DRUG MPH (Ritalin)
- DRUG Atomoxetine (ATO)
- DRUG Guanfacine (GFC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17,418 participants |
| Start Date | 2019-10-01 |
| Est. Completion | 2020-01-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04113551
The ClinicalTrials.gov registry entry for NCT04113551 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 17,418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which MPH (Concerta) is the first listed.
NCT04113551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04113551 about?
NCT04113551 is a clinical study titled "A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan". The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
What is the current status of trial NCT04113551?
This trial is currently completed. The enrollment target is 17,418 participants. The study started on 2019-10-01. Estimated completion is 2020-01-10.
What interventions are being tested in trial NCT04113551?
The interventions under investigation include: MPH (Concerta) (DRUG), MPH (Ritalin) (DRUG), Atomoxetine (ATO) (DRUG), Guanfacine (GFC) (DRUG).
Who is sponsoring clinical trial NCT04113551?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.